WO2007025247A3 - Transglutaminase inhibitors and methods of use thereof - Google Patents

Transglutaminase inhibitors and methods of use thereof Download PDF

Info

Publication number
WO2007025247A3
WO2007025247A3 PCT/US2006/033486 US2006033486W WO2007025247A3 WO 2007025247 A3 WO2007025247 A3 WO 2007025247A3 US 2006033486 W US2006033486 W US 2006033486W WO 2007025247 A3 WO2007025247 A3 WO 2007025247A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
transglutaminase inhibitors
transglutaminase
inhibitors
Prior art date
Application number
PCT/US2006/033486
Other languages
French (fr)
Other versions
WO2007025247A2 (en
Inventor
Chaitan Khosla
Richard Edward Watts
Matthew John Siegel
Daniel M Pinkas
Kihang Choi
Keith M Rich
Original Assignee
Univ Leland Stanford Junior
Univ Washington
Chaitan Khosla
Richard Edward Watts
Matthew John Siegel
Daniel M Pinkas
Kihang Choi
Keith M Rich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior, Univ Washington, Chaitan Khosla, Richard Edward Watts, Matthew John Siegel, Daniel M Pinkas, Kihang Choi, Keith M Rich filed Critical Univ Leland Stanford Junior
Priority to US12/064,800 priority Critical patent/US8470782B2/en
Priority to EP06813841A priority patent/EP1931205A4/en
Publication of WO2007025247A2 publication Critical patent/WO2007025247A2/en
Publication of WO2007025247A3 publication Critical patent/WO2007025247A3/en
Priority to US13/693,804 priority patent/US8871718B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Abstract

Transglutaminase inhibitors and methods of use thereof are provided.
PCT/US2006/033486 2005-08-26 2006-08-28 Transglutaminase inhibitors and methods of use thereof WO2007025247A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US12/064,800 US8470782B2 (en) 2005-08-26 2006-08-28 Transglutaminase inhibitors and methods of use thereof
EP06813841A EP1931205A4 (en) 2005-08-26 2006-08-28 Transglutaminase inhibitors and methods of use thereof
US13/693,804 US8871718B2 (en) 2005-08-26 2012-12-04 Transglutaminase inhibitors and methods of use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/213,173 2005-08-26
US11/213,173 US7579313B2 (en) 2003-11-18 2005-08-26 Transglutaminase inhibitors and methods of use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/213,173 Division US7579313B2 (en) 2003-11-18 2005-08-26 Transglutaminase inhibitors and methods of use thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/064,800 A-371-Of-International US8470782B2 (en) 2005-08-26 2006-08-28 Transglutaminase inhibitors and methods of use thereof
US13/693,804 Division US8871718B2 (en) 2005-08-26 2012-12-04 Transglutaminase inhibitors and methods of use thereof

Publications (2)

Publication Number Publication Date
WO2007025247A2 WO2007025247A2 (en) 2007-03-01
WO2007025247A3 true WO2007025247A3 (en) 2007-11-22

Family

ID=37772503

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/033486 WO2007025247A2 (en) 2005-08-26 2006-08-28 Transglutaminase inhibitors and methods of use thereof

Country Status (3)

Country Link
US (4) US7579313B2 (en)
EP (1) EP1931205A4 (en)
WO (1) WO2007025247A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE505201T1 (en) 2002-02-14 2011-04-15 Univ Leland Stanford Junior ENZYME TREATMENT OF FOODS FOR CELIAIC SPRAY
US8143210B2 (en) 2002-02-14 2012-03-27 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
US7202216B2 (en) * 2002-05-14 2007-04-10 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US7462688B2 (en) * 2002-05-14 2008-12-09 The Board Of Trustees Of The Leland Stanford Junior University Peptides for diagnostic and therapeutic methods for celiac sprue
CA2487247A1 (en) * 2002-05-14 2003-11-27 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US7265093B2 (en) * 2002-05-14 2007-09-04 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for Celiac Sprue
EP1563300B1 (en) * 2002-11-20 2012-04-18 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic method for celiac sprue
US7579313B2 (en) * 2003-11-18 2009-08-25 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
WO2007050795A2 (en) * 2005-10-25 2007-05-03 Alvine Pharmaceuticals, Inc. Transglutaminase inhibitors and methods of use thereof
WO2008060368A2 (en) * 2006-10-02 2008-05-22 Duke University Transglutaminase-binding peptides and methods of use
US8148105B2 (en) * 2007-03-16 2012-04-03 The Board Of Trustees Of The Leland Stanford Junior University Scaleable manufacturing process for cysteine endoprotease B, isoform 2
AU2008229448B2 (en) * 2007-03-16 2013-01-24 The Board Of Trustees Of The Leland Stanford Junior University Combination enzyme therapy for digestion of dietary gluten
ES2343499B1 (en) 2007-12-24 2011-06-10 Consejo Superior De Investigaciones Cientificas MICROORGANISMS TO IMPROVE THE STATE OF HEALTH OF INDIVIDUALS WITH DISORDERS RELATED TO THE INTAKE OF GLUTEN.
WO2012078519A2 (en) * 2010-12-06 2012-06-14 Numerate, Inc. 3-acylidene-2-oxoindole derivatives for inhibition of transglutaminase 2
JP2014520147A (en) * 2011-06-20 2014-08-21 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ Regulation of tissue transglutaminase activation in disease
ES2667418T3 (en) 2011-08-10 2018-05-10 University Of Washington Through Its Center For Commercialization Compositions and methods for the treatment of celiac disease
WO2015023728A1 (en) 2013-08-14 2015-02-19 University Of Washington Through Its Center For Commercialization Compositions and methods for treating celiac sprue disease
WO2015116846A1 (en) * 2014-01-30 2015-08-06 The Board Of Trustees Of The Leland Stanford Junior University Modulation of tissue transglutaminase activation in disease
KR20180023903A (en) 2015-06-08 2018-03-07 유니버시티 오브 워싱턴 Compositions and methods for treating Celiac sprue disease
FI3328827T3 (en) 2015-07-31 2023-09-26 Univ Johns Hopkins Prodrugs of glutamine analogs
WO2017023787A1 (en) 2015-07-31 2017-02-09 The Johns Hopkins University Methods and compositions for treating metabolic reprogramming disorders
US10842763B2 (en) * 2015-07-31 2020-11-24 The Johns Hopkins University Methods for cancer and immunotherapy using prodrugs of glutamine analogs
TWI825144B (en) * 2018-08-10 2023-12-11 美商思達利醫藥公司 Transglutaminase 2 (tg2) inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030224476A1 (en) * 2002-03-01 2003-12-04 Szu-Yi Chou Method of producing transglutaminase reactive compound
US20040167069A1 (en) * 2002-05-14 2004-08-26 Chaitan Khosla Drug therapy for Celiac Sprue
US20050090653A1 (en) * 2001-11-28 2005-04-28 Jo Klaveness Metal complex compounds

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE262999C (en)
NL7414128A (en) 1973-10-31 1975-05-02 James Joseph Phelan PROCESS FOR THE DETOXIFICATION OF GLUTEN.
US4203967A (en) 1977-01-13 1980-05-20 Hoffmann-La Roche Inc. Diagnostic test for malabsorption
US4562003A (en) * 1984-10-26 1985-12-31 California Biotechnology, Inc. Monoclonal antibodies against alveolar surfactant protein
KR900006545B1 (en) 1986-03-14 1990-09-13 신텍스(미합중국) 인코포레이티드 Transglutaminase inhibitors
US4912120A (en) 1986-03-14 1990-03-27 Syntex (U.S.A.) Inc. 3,5-substituted 4,5-dihydroisoxazoles as transglutaminase inhibitors
US4929630A (en) 1986-03-14 1990-05-29 Syntex (U.S.A.) Inc. Transglutaminase inhibitors
US5208021A (en) * 1987-10-05 1993-05-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of preparing diphtheria immunotoxins
US5372933A (en) * 1988-10-03 1994-12-13 The Scripps Research Institute Polypeptides that mimic receptor-induced binding sites, and methods of using same
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5811098A (en) * 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
GB9225021D0 (en) * 1992-11-30 1993-01-20 Sandoz Ltd Organic compounds
WO1994026774A1 (en) 1993-05-19 1994-11-24 Cytel Corporation Novel treatments for allergic diseases
US6197356B1 (en) 1993-08-03 2001-03-06 Immunopath Profile, Inc. Process for preparing hypoallergenic foods
US5663304A (en) * 1993-08-20 1997-09-02 Genentech, Inc. Refolding of misfolded insulin-like growth factor-I
WO1995021190A1 (en) * 1994-02-07 1995-08-10 The United States Of America, Represented By The Secretary Of Agriculture Detection of wheat that has experienced elevated temperatures during the grain filling period
WO1996010034A2 (en) 1994-09-29 1996-04-04 Merck & Co., Inc. Thiol-free inhibitors of farnesyl-protein transferase
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
GB9509336D0 (en) * 1995-05-09 1995-06-28 Dynal As Chemical method
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US20020018763A1 (en) * 1995-05-24 2002-02-14 Kriszkina M. Zsebo A method of stimulating growth of stromal cells with stem cell factor (scf) polypeptides
DE19630557C2 (en) 1996-07-18 1998-07-02 Schuppan Detlef Priv Doz Dr Dr Method for the detection of antibodies from body fluids by an immune reaction with tissue transglutaminase (tTG) as well as the use of tTG in diagnosis and therapy
US7696338B2 (en) * 1995-10-30 2010-04-13 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin fusion proteins and means for expression thereof
US5716794A (en) * 1996-03-29 1998-02-10 Xybernaut Corporation Celiac antigen
US5817523A (en) 1996-07-24 1998-10-06 Picarelli; Antonio Method and kit for confirming in vitro diagnosis of coeliac disease
US5912327A (en) * 1996-09-30 1999-06-15 Human Genome Sciences, Inc. Method of purifying chemokines from inclusion bodies
US6635462B1 (en) * 1997-05-12 2003-10-21 Phoenix Pharmacologies, Inc. Mutated form of arginine deiminase
EP0905518A1 (en) 1997-09-23 1999-03-31 Academisch Ziekenhuis Leiden Peptides specific for gluten-sensitive T-cells and use thereof
US20020052026A1 (en) * 1997-10-08 2002-05-02 Steven M. Vicik Methods of refolding proteins
PL209404B1 (en) 1997-12-31 2011-08-31 Pfizer Prod Inc Aryl-condensed azapolycyclic compounds
EP1075267A2 (en) 1998-05-06 2001-02-14 Kobenhavns Universitet Treatment of celiac disease
US6201695B1 (en) * 1998-10-26 2001-03-13 Micron Technology, Inc. Heat sink for chip stacking applications
US6294320B1 (en) * 1998-12-04 2001-09-25 Barnes-Jewish Hospital Cell matrix plaques of initial bone formation
CA2360581A1 (en) 1999-01-13 2000-07-20 The Research Foundation Of State University Of New York A novel method for designing protein kinase inhibitors
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
US6962989B1 (en) * 1999-07-08 2005-11-08 Basf Aktiengesellschaft Corynebacterium glutamicum genes encoding novel proteins
US6395889B1 (en) * 1999-09-09 2002-05-28 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding human protease homologs
GB9923306D0 (en) 1999-10-01 1999-12-08 Isis Innovation Diagnostic and therapeutic epitope, and transgenic plant
WO2001029078A2 (en) * 1999-10-15 2001-04-26 Heska Corporation Method for production and use of mite group 1 proteins
US6492498B1 (en) * 1999-11-15 2002-12-10 Regents Of The University Of Minnesota Multimeric immunotoxins
US6667160B2 (en) 2000-03-15 2003-12-23 Kenneth D. Fine Method for diagnosing immunologic food sensitivity
US6642036B2 (en) * 2000-07-07 2003-11-04 E. I. Du Pont De Nemours And Company Sinapoylglucose:malate sinapoyltransferase form malate conjugates from benozic acid glucosides
US6833447B1 (en) * 2000-07-10 2004-12-21 Monsanto Technology, Llc Myxococcus xanthus genome sequences and uses thereof
EP1201136A1 (en) * 2000-10-31 2002-05-02 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Food grade transglutaminase inhibitor and uses thereof
PT1326957E (en) 2000-12-07 2004-09-30 Dsm Ip Assets Bv METHOD FOR THE PREVENTION OR REDUCTION OF FLAVORING IN BEVERAGES
CA2437081C (en) 2000-12-07 2010-10-19 Dsm Ip Assets B.V. Protein hydrolysates enriched in peptides having a carboxy terminal proline residue
EP1360192A1 (en) * 2001-01-16 2003-11-12 Kobenhavns Universitet A method for refolding of proteins
US7442370B2 (en) * 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
WO2003004273A1 (en) 2001-07-04 2003-01-16 Any Seyd Ahmadiyan Device for carrying out zonal ink dosing, and an actuator comprising an actuating wire made of a shape memory alloy
US6645739B2 (en) * 2001-07-26 2003-11-11 Phoenix Pharmacologies, Inc. Yeast expression systems, methods of producing polypeptides in yeast, and compositions relating to same
EP1332760A1 (en) * 2002-02-04 2003-08-06 Academisch Ziekenhuis Leiden Novel epitopes for celiac disease and autoimmune diseases, methods for detecting those and novel non-antigenic food compounds
US7320788B2 (en) * 2002-02-14 2008-01-22 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for Celiac Sprue
ATE505201T1 (en) 2002-02-14 2011-04-15 Univ Leland Stanford Junior ENZYME TREATMENT OF FOODS FOR CELIAIC SPRAY
CA2487247A1 (en) 2002-05-14 2003-11-27 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US7202216B2 (en) * 2002-05-14 2007-04-10 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US7462688B2 (en) * 2002-05-14 2008-12-09 The Board Of Trustees Of The Leland Stanford Junior University Peptides for diagnostic and therapeutic methods for celiac sprue
US6903246B2 (en) * 2002-05-28 2005-06-07 The Regents Of The University Of California Dehydroascorbate reductase (“DHAR”) genes from Triticum aestivum and their use to modulate ascorbic acid levels in plants
GB0212885D0 (en) 2002-06-05 2002-07-17 Isis Innovation Therapeutic epitopes and uses thereof
EP1563300B1 (en) * 2002-11-20 2012-04-18 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic method for celiac sprue
CN1311076C (en) * 2003-04-16 2007-04-18 普罗特奥姆技术公司 Method for producing recombinaton urokinase
US20050049064A1 (en) * 2003-09-02 2005-03-03 Gagne Robert M. Golf training apparatus
US7579313B2 (en) * 2003-11-18 2009-08-25 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
US20050227920A1 (en) * 2003-12-11 2005-10-13 Xinli Lin Methods for production of recombinant vascular endothelial cell growth inhibitor
US7534426B2 (en) * 2004-04-26 2009-05-19 The Board Of Trustees Of The Leland Stanford Junior University Glutenase enzyme assays
US7521427B2 (en) * 2004-11-09 2009-04-21 Georgia Tech Research Corporation Peptidyl allyl sulfones
US8119125B2 (en) * 2005-10-11 2012-02-21 Alvine Pharmaceuticals, Inc. Compositions and methods for enhanced gastrointestinal stability of oligopeptides and polypeptides
WO2007047303A2 (en) * 2005-10-12 2007-04-26 Alvine Pharmaceuticals, Inc. Pegylated glutenase polypeptides
WO2007050795A2 (en) * 2005-10-25 2007-05-03 Alvine Pharmaceuticals, Inc. Transglutaminase inhibitors and methods of use thereof
US20070099238A1 (en) * 2005-10-31 2007-05-03 Sigalas Mihail M Enhancement of emission using metal coated dielectric nanoparticles
EP1845103B1 (en) * 2006-04-10 2015-02-25 Boehringer Ingelheim RCV GmbH & Co KG Method for refolding a protein
US8148105B2 (en) 2007-03-16 2012-04-03 The Board Of Trustees Of The Leland Stanford Junior University Scaleable manufacturing process for cysteine endoprotease B, isoform 2
AU2008229448B2 (en) 2007-03-16 2013-01-24 The Board Of Trustees Of The Leland Stanford Junior University Combination enzyme therapy for digestion of dietary gluten
AU2009283157B2 (en) 2008-08-21 2015-02-26 Alvine Pharmaceuticals, Inc. Formulation for oral administration of proteins
US9017667B2 (en) 2008-10-10 2015-04-28 Alvine Pharmaceuticals, Inc. Dosage forms that facilitate rapid activation of barley protease zymogen

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050090653A1 (en) * 2001-11-28 2005-04-28 Jo Klaveness Metal complex compounds
US20030224476A1 (en) * 2002-03-01 2003-12-04 Szu-Yi Chou Method of producing transglutaminase reactive compound
US20040167069A1 (en) * 2002-05-14 2004-08-26 Chaitan Khosla Drug therapy for Celiac Sprue

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1931205A4 *

Also Published As

Publication number Publication date
US20090312272A1 (en) 2009-12-17
EP1931205A2 (en) 2008-06-18
US20060052308A1 (en) 2006-03-09
US20130102633A1 (en) 2013-04-25
US20090042806A1 (en) 2009-02-12
US7579313B2 (en) 2009-08-25
US8470782B2 (en) 2013-06-25
WO2007025247A2 (en) 2007-03-01
US8871718B2 (en) 2014-10-28
EP1931205A4 (en) 2009-11-11
US8153593B2 (en) 2012-04-10

Similar Documents

Publication Publication Date Title
WO2007025247A3 (en) Transglutaminase inhibitors and methods of use thereof
WO2007050795A3 (en) Transglutaminase inhibitors and methods of use thereof
WO2007025169A3 (en) Hif inhibitors
EP1863769A4 (en) Hsp90 inhibitors, methods of making and uses therefor
EP1835929B8 (en) Anti-kir combination treatments and methods
WO2007070538A9 (en) Anti-mn antibodies and methods of using same
IL213342A0 (en) Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
EP1812049A4 (en) Kallikrein inhibitors and uses thereof
EP1869060A4 (en) Selective glycosidase inhibitors, methods of making inhibitors, and uses thereof
GB0505970D0 (en) Culture medium containing kinase inhibitor, and uses thereof
ZA200704888B (en) Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
WO2005079300A9 (en) Protein kinase inhibitors and methods for identifying same
EP1922086A4 (en) Targeted protein kinase c inhibitors and uses thereof
WO2006036394A3 (en) Methods for making retinoids and uses thereof
EP1877424A4 (en) Inhibitors of protein kinases and uses thereof
IL181819A0 (en) Enzyme inhibitors and uses thereof
IL187728A0 (en) Benzooxazole-2-on derivatives as lipase and phospholipase inhibitors
EP1850130A4 (en) Gene markers and utilzation of the same
IL177647A0 (en) Use of enzyme
WO2007016364A3 (en) Peptide deformylase inhibitors
EP1978999A4 (en) Isolated mcpip and methods of use
EP1933820A4 (en) Palmarumycin based inhibitors of thioredoxin and methods of using same
AU2004905182A0 (en) Enzyme inhibitors and uses thereof
GB0417408D0 (en) Enzyme inhibitors
GB0410302D0 (en) Enzyme inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006813841

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12064800

Country of ref document: US